ERBB2 and familial pancreatic carcinoma: Similarly, amplification or overexpression of AKT2 has been identified in HER2/neu positive (Her2/neu+) breast cancers as well as ovarian, prostate and pancreatic cancers correlating with poor prognosis, and increased risk of relapse and metastatic tumor formation [27–30].